Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + Apatinib for Perioperative Resectable HCC
NCT04521153Phase 3Active, not recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Mar 2021
- Primary completion
- Jul 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 3 trial of camrelizumab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Started Mar 2021; status: active, not recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04521153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04521153.